Supplementary Material - ECZTEND Interim Analysis Manuscript (2 years tralokinumab treatment)
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
Supplementary Information to accompany and support the manuscript: Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.
创建时间：
2022-07-12
